Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Hoechst and Rhone-Poulenc announced a merger of their pharmaceutical and agricultural businesses to form Aventis, creating the second-largest pharmaceuticals…
Executives stated they want to create a new company with European roots and global reach to take full advantage of life sciences opportunities in the…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Hoechst AG and Rhone-Poulenc S.A. merged their life sciences businesses to create Aventis, then one of the world's largest pharmaceutical companies with combined revenue of approximately $20 billion. The merger was implemented through an exchange offer with Hoechst shareholders receiving Rhone-Poulenc shares at a 4:3 ratio.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Rhone-Poulenc S.A. / Hoechst AG (this deal) | 1998 | $21.2B | 74 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Astra AB / Zeneca Group plc | 1998 | $35.0B | 94 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
← Browse all deals · How we score deals
More: 1998 deals · Cardiovascular deals